The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 10, 2015

Filed:

Oct. 06, 2009
Applicants:

John D. Shaughnessy, Jr., Roland, AR (US);

Bart Barlogie, Little Rock, AR (US);

Fenghuang Zhan, Salt Lake City, UT (US);

Inventors:

John D. Shaughnessy, Jr., Roland, AR (US);

Bart Barlogie, Little Rock, AR (US);

Fenghuang Zhan, Salt Lake City, UT (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/50 (2006.01); C12Q 1/68 (2006.01); G06F 19/18 (2011.01); G06F 19/24 (2011.01); G06F 19/20 (2011.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); C12Q 2600/106 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/136 (2013.01); G06F 19/18 (2013.01); G06F 19/20 (2013.01); C12Q 1/6841 (2013.01); G06F 19/24 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/112 (2013.01);
Abstract

Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogenesis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.


Find Patent Forward Citations

Loading…